Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 14/20 | 0.81 |
| ▸ | CASP8 | Q14790 | 3/20 | 0.63 |
| ▸ | CASP3 | P42574 | 2/20 | 0.63 |
| ▸ | IL1B | P01584 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 5/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200428 | 0.91 | CASP1 (0.88) | CASP1CASP8CASP3IL1BLCK | |
| SCHEMBL16883405 | 0.91 | CASP1 (0.88) | CASP1CASP8CASP3IL1BLCK | |
| Vrt-18858 SCHEMBL647044 | 0.90 | CASP1 (1.00) | CASP1CASP8CASP3IL1BLCK | |
| Vrt-18858 SCHEMBL646101 | 0.90 | CASP1 (1.00) | CASP1CASP8CASP3IL1BLCK | |
| Vrt-18858 SCHEMBL30070800 | 0.90 | CASP1 (1.00) | CASP1CASP8CASP3IL1BLCK | |
| SCHEMBL10199344 | 0.86 | CASP1 (0.80) | CASP1CASP8CASP3IL1BLCK | |
| SCHEMBL10247884 | 0.86 | CASP1 (0.80) | CASP1CASP8CASP3IL1BLCK | |
| SCHEMBL8284807 | 0.85 | CASP1 (0.79) | CASP1CASP8CASP3IL1BLCK | |
| SCHEMBL2216769 | 0.79 | CASP1 (0.73) | CASP1CASP8CASP3IL1BLCK | |
| SCHEMBL656822 | 0.79 | CASP1 (0.68) | CASP1CASP8CASP3IL1BLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2083014-A2 | Inhibitors of interleukin-1ß converting enzyme | Vertex Pharmceuticals Incorporated (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-04 | — | — | US | disclosed |
| US-6423840-B1 | FORMING N-ACYLAMINO COMPOUND | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-23 | — | — | US | disclosed |
| US-6258948-B1 | AN N-ACYLAMINO COMPOUND; ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED | 2001-07-10 | — | — | US | disclosed |
| US-5985863-A | PHARMACEUTICAL COMPOSITIONS FOR DECREASING THE PRODUCTION OF INTERFERON-GAMMA INDUCING FACTOR (IGIF), AND INTERFERON-GAMMA (IFN-GAMMA) COMPRISING COMPOUND WHICH INHIBITS INTERLEUKIN-1.BETA. CONVERTING ENZYME (ICE) | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885CASP8 131/4885CASP3 85/4885 |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, APAF1, IL1B | CASP1 6/4885CASP8 120/4885CASP3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.